TY - JOUR
T1 - Advancing vaccine-based immunotherapy in glioblastoma treatment
AU - Singh, Desh Deepak
AU - Haque, Shafiul
AU - Singh, Abhishek Kumar
AU - Yadav, Dharmendra Kumar
N1 - Publisher Copyright:
© The Author(s) 2025. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - Glioblastomas (GBMs) originate from glial cells and are characterized by aggressive growth and poor prognosis. Despite advances in surgical resection, complete elimination remains challenging, often leading to recurrence that is resistant to standard therapies. Immunotherapy and conventional treatments show promise in enhancing therapeutic outcomes across various cancers. Researchers continue to explore new treatments, particularly radiation, chemotherapy, and surgery; however, glioblastoma remains highly challenging, with only modest improvements in survival. Recent progress in immunotherapy, especially with tumor vaccines such as peptide-based and cell-based options (eg, dendritic cell vaccines), represents significant advancements despite the limitations observed in current clinical trials.This article reviews recent developments in vaccine-based immunotherapy for glioblastoma treatment.
AB - Glioblastomas (GBMs) originate from glial cells and are characterized by aggressive growth and poor prognosis. Despite advances in surgical resection, complete elimination remains challenging, often leading to recurrence that is resistant to standard therapies. Immunotherapy and conventional treatments show promise in enhancing therapeutic outcomes across various cancers. Researchers continue to explore new treatments, particularly radiation, chemotherapy, and surgery; however, glioblastoma remains highly challenging, with only modest improvements in survival. Recent progress in immunotherapy, especially with tumor vaccines such as peptide-based and cell-based options (eg, dendritic cell vaccines), represents significant advancements despite the limitations observed in current clinical trials.This article reviews recent developments in vaccine-based immunotherapy for glioblastoma treatment.
UR - https://www.scopus.com/pages/publications/105012380830
U2 - 10.1093/noajnl/vdaf135
DO - 10.1093/noajnl/vdaf135
M3 - Artículo de revisión
AN - SCOPUS:105012380830
SN - 2632-2498
VL - 7
JO - Neuro-Oncology Advances
JF - Neuro-Oncology Advances
IS - 1
M1 - vdaf135
ER -
